$SGMO
Sangamo Therapeutics Inc Stock $sgmo

$sgmo Overview Financials Valuation SEC Filings Company Website

2020 Q1 Form 10-Q Financial Statement

#000162828020007462 Filed on May 11, 2020

Income Statement

Concept	2020 Q1	2019 Q1
Revenue	$13.08M	$8.071M
YoY Change	62.01%	-36.13%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$16.12M	$17.12M
YoY Change	-5.84%	69.67%
% of Gross Profit
Research & Development	$41.48M	$34.85M
YoY Change	19.02%	48.0%
% of Gross Profit
Depreciation & Amortization	$1.311M	$715.0K
YoY Change	83.36%	21.6%
% of Gross Profit
Operating Expenses	$57.60M	$51.97M
YoY Change	10.83%	54.51%
Operating Profit	-$44.52M	-$43.90M
YoY Change	1.42%	109.06%
Interest Expense	$1.550M	$1.690M
YoY Change	-8.28%	108.64%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$42.97M	-$42.20M
YoY Change	1.82%	109.01%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$42.91M	-$42.15M
YoY Change	1.81%	108.8%
Net Earnings / Revenue	-328.18%	-522.24%
Basic Earnings Per Share
Diluted Earnings Per Share	-$369.7K	-$412.1K
COMMON SHARES
Basic Shares Outstanding	116.0M shares	102.3M
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q1	2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$358.1M	$351.0M
YoY Change	2.03%	52.94%
Cash & Equivalents	$85.75M	$80.97M
Short-Term Investments	$272.4M	$270.0M
Other Short-Term Assets	$4.900M	$3.700M
YoY Change	32.43%	32.14%
Inventory
Prepaid Expenses
Receivables	$6.970M	$7.300M
Other Receivables	$900.0K	$600.0K
Total Short-Term Assets	$370.9M	$362.6M
YoY Change	2.3%	53.45%
LONG-TERM ASSETS
Property, Plant & Equipment	$31.29M	$46.50M
YoY Change	-32.7%	38.39%
Goodwill	$38.55M
YoY Change
Intangibles	$52.14M	$53.17M
YoY Change	-1.94%
Long-Term Investments	$5.000M
YoY Change
Other Assets	$9.470M	$41.20M
YoY Change	-77.01%	776.6%
Total Long-Term Assets	$213.3M	$180.1M
YoY Change	18.45%	301.11%
TOTAL ASSETS
Total Short-Term Assets	$370.9M	$362.6M
Total Long-Term Assets	$213.3M	$180.1M
Total Assets	$584.3M	$542.7M
YoY Change	7.66%	92.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$13.60M	$30.10M
YoY Change	-54.82%	173.64%
Accrued Expenses	$11.90M	$6.200M
YoY Change	91.94%	93.75%
Deferred Revenue	$36.55M	$54.82M
YoY Change	-33.33%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$62.07M	$91.10M
YoY Change	-31.87%	84.41%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change		-100.0%
Other Long-Term Liabilities	$5.880M	$1.911M
YoY Change	207.69%	-92.04%
Total Long-Term Liabilities	$5.880M	$1.911M
YoY Change	207.69%	-96.13%
TOTAL LIABILITIES
Total Short-Term Liabilities	$62.07M	$91.10M
Total Long-Term Liabilities	$5.880M	$1.911M
Total Liabilities	$189.9M	$214.2M
YoY Change	-11.36%	116.8%
SHAREHOLDERS EQUITY
Retained Earnings	-$699.9M
YoY Change
Common Stock	$1.098B
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$394.3M	$328.5M
YoY Change
Total Liabilities & Shareholders Equity	$584.3M	$542.7M
YoY Change	7.66%	93.03%

Cashflow Statement

Concept	2020 Q1	2019 Q1
OPERATING ACTIVITIES
Net Income	-$42.91M	-$42.15M
YoY Change	1.81%	108.8%
Depreciation, Depletion And Amortization	$1.311M	$715.0K
YoY Change	83.36%	21.6%
Cash From Operating Activities	-$18.89M	-$45.12M
YoY Change	-58.13%	148.81%
INVESTING ACTIVITIES
Capital Expenditures	$3.775M	$5.977M
YoY Change	-36.84%	128.48%
Acquisitions
YoY Change
Other Investing Activities	$27.50M	-$8.800M
YoY Change	-412.5%	-2.22%
Cash From Investing Activities	$23.72M	-$14.80M
YoY Change	-260.28%	27.94%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00	$481.0K
YoY Change	-100.0%	-95.46%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$409.0K	$216.0K
YoY Change	89.35%	-97.96%
NET CHANGE
Cash From Operating Activities	-$18.89M	-$45.12M
Cash From Investing Activities	$23.72M	-$14.80M
Cash From Financing Activities	$409.0K	$216.0K
Net Change In Cash	$5.321M	-$59.45M
YoY Change	-108.95%	210.96%
FREE CASH FLOW
Cash From Operating Activities	-$18.89M	-$45.12M
Capital Expenditures	$3.775M	$5.977M
Free Cash Flow	-$22.67M	-$51.10M
YoY Change	-55.64%	146.25%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020Q1	dei	Amendment Flag AmendmentFlag	false
CY2020Q1	dei	Local Phone Number LocalPhoneNumber	970-6000
CY2020Q1	dei	City Area Code CityAreaCode	510
CY2020Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2020Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001001233
CY2020Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q1	dei	Document Type DocumentType	10-Q
CY2020Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2020Q1	dei	Document Period End Date DocumentPeriodEndDate	2020-03-31
CY2020Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2020Q1	dei	Entity File Number EntityFileNumber	000-30171
CY2020Q1	dei	Entity Registrant Name EntityRegistrantName	SANGAMO THERAPEUTICS, INC.
CY2020Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	68-0359556
CY2020Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	7000 Marina Blvd.
CY2020Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Brisbane
CY2020Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2020Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94005
CY2020Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01 per share
CY2020Q1	dei	Trading Symbol TradingSymbol	SGMO
CY2020Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2020Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2020Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020Q1	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	140883058	shares
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	85749000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	80428000	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	272381000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	282046000	USD
CY2020Q1	us-gaap	Interest Receivable Current InterestReceivableCurrent	926000	USD
CY2019Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	682000	USD
CY2020Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6970000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	36909000	USD
CY2020Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4922000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5408000	USD
CY2020Q1	us-gaap	Assets Current AssetsCurrent	370948000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	405473000	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	5000000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	21832000	USD
CY2020Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	31294000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	29926000	USD
CY2020Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	52137000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	53156000	USD
CY2020Q1	us-gaap	Goodwill Goodwill	38550000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	39273000	USD
CY2020Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	75377000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	77289000	USD
CY2020Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-699898000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-656985000	USD
CY2020Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	9470000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	9067000	USD
CY2020Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1500000	USD
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1500000	USD
CY2020Q1	us-gaap	Assets Assets	584276000	USD
CY2019Q4	us-gaap	Assets Assets	637516000	USD
CY2020Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	16923000	USD
CY2019Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	17556000	USD
CY2020Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	8592000	USD
CY2019Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	13605000	USD
CY2020Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	36550000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	38711000	USD
CY2020Q1	us-gaap	Liabilities Current LiabilitiesCurrent	62065000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	69872000	USD
CY2020Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	75274000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	81432000	USD
CY2020Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	40198000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	41192000	USD
CY2020Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	6444000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	6570000	USD
CY2020Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5880000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5711000	USD
CY2020Q1	us-gaap	Liabilities Liabilities	189861000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	204777000	USD
CY2020Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q1	us-gaap	Common Stock Value CommonStockValue	1163000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	1160000	USD
CY2020Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1096854000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1090828000	USD
CY2020Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3828000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2449000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	394291000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	432554000	USD
CY2020Q1	us-gaap	Minority Interest MinorityInterest	124000	USD
CY2019Q4	us-gaap	Minority Interest MinorityInterest	185000	USD
CY2020Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	394415000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	432739000	USD
CY2020Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	584276000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	637516000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13076000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8071000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	41479000	USD
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	34850000	USD
CY2020Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16119000	USD
CY2019Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17118000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	57598000	USD
CY2020Q1	us-gaap	Interest And Other Income InterestAndOtherIncome	1548000	USD
CY2019Q1	us-gaap	Interest And Other Income InterestAndOtherIncome	1694000	USD
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	51968000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-44522000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-43897000	USD
CY2020Q1	us-gaap	Profit Loss ProfitLoss	-42974000	USD
CY2019Q1	us-gaap	Profit Loss ProfitLoss	-42203000	USD
CY2020Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-61000	USD
CY2019Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-53000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-42913000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-42150000	USD
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.37
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.41
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	116060000	shares
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	102270000	shares
CY2020Q1	us-gaap	Profit Loss ProfitLoss	-42974000	USD
CY2019Q1	us-gaap	Profit Loss ProfitLoss	-42203000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1633000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1504000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	254000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	253000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-44353000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-43454000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-61000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-53000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-44292000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-43401000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	432739000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	409000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5620000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	1633000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	254000	USD
CY2020Q1	us-gaap	Profit Loss ProfitLoss	-42974000	USD
CY2020Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	394415000	USD
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	367257000	USD
CY2019Q1	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	897000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	216000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	258000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4523000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	1504000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	253000	USD
CY2019Q1	us-gaap	Profit Loss ProfitLoss	-42203000	USD
CY2019Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	329181000	USD
CY2020Q1	us-gaap	Profit Loss ProfitLoss	-42974000	USD
CY2019Q1	us-gaap	Profit Loss ProfitLoss	-42203000	USD
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1311000	USD
CY2019Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	715000	USD
CY2020Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	744000	USD
CY2019Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1238000	USD
CY2020Q1	sgmo	Amortization And Other Changes In Right Of Use Assets AmortizationAndOtherChangesInRightOfUseAssets	-1886000	USD
CY2019Q1	us-gaap	Increase Decrease In Prepaid Rent IncreaseDecreaseInPrepaidRent	12101000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	345000	USD
CY2019Q1	sgmo	Amortization And Other Changes In Right Of Use Assets AmortizationAndOtherChangesInRightOfUseAssets	-782000	USD
CY2020Q1	sgmo	Gain Loss On Free Shares GainLossOnFreeShares	-73000	USD
CY2019Q1	sgmo	Gain Loss On Free Shares GainLossOnFreeShares	545000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	5620000	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4523000	USD
CY2020Q1	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	0	USD
CY2019Q1	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	-218000	USD
CY2020Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	USD
CY2019Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-44000	USD
CY2020Q1	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	244000	USD
CY2019Q1	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	219000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-29939000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2638000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	100000	USD
CY2019Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1152000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Rent IncreaseDecreaseInPrepaidRent	0	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	10183000	USD
CY2020Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-4965000	USD
CY2019Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-3306000	USD
CY2020Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-8319000	USD
CY2019Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-370000	USD
CY2020Q1	sgmo	Increase Decrease In Long Term Portion Of Lease Liabilities IncreaseDecreaseInLongTermPortionOfLeaseLiabilities	-887000	USD
CY2019Q1	sgmo	Increase Decrease In Long Term Portion Of Lease Liabilities IncreaseDecreaseInLongTermPortionOfLeaseLiabilities	-66000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	169000	USD
CY2019Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-50000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18890000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-45119000	USD
CY2020Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	43580000	USD
CY2019Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	87075000	USD
CY2020Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	71075000	USD
CY2019Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	78253000	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3775000	USD
CY2020Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	411000	USD
CY2019Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	265000	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	820000	USD
CY2019Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	481000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	409000	USD
CY2019Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5977000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	23720000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-14799000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	216000	USD
CY2020Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	82000	USD
CY2019Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	252000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5321000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-59450000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	81928000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	143918000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	87249000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	84468000	USD
CY2020Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1080000	USD
CY2019Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1834000	USD
CY2020Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2019Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	6676000	USD
CY2020Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value of assets and liabilities, including from acquisitions, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2020, the Company recorded an adjustment to revenue related to a change in estimate in connection with the collaboration agreement with Sanofi Genzyme (“Sanofi”) as result of a decision made by the joint steering committee of Sanofi and Sangamo to increase the project scope and related project cost, which resulted in a decrease in the measure of proportional cumulative performance. In March 2020, the Company also recorded an adjustment to revenue related to a change in estimate in connection with the hemophilia A collaboration agreement with Pfizer Inc. (“Pfizer”). This adjustment was a direct result of the decision to decrease the project scope and the corresponding costs after the successful investigational new drug (“IND”) transfer of the SB-525 product candidate to Pfizer, both of which resulted in an increase in the measure of proportional cumulative performance. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These adjustments increased revenue by $0.1 million, decreased net loss by $0.1 million and no impact on the Company’s basic net loss per share for the three months ended March 31, 2020.</span></div><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for its revenues pursuant to the provisions of Accounting Standards Codification (“ASC”) Topic 606, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue from Contracts with Customers</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (“ASC Topic 606”). The Company’s contract revenues are derived from collaboration agreements including licensing arrangements and research activity grants. Research and licensing agreements typically include upfront signing or license fees, cost reimbursements for research services, minimum sublicense fees, milestone payments and royalties on future licensee’s product sales. The Company has agreements with both fixed and variable consideration. Non-refundable upfront fees and funding of research and development activities are considered fixed, while milestone payments are generally identified as variable consideration. Sangamo’s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenues under research grant agreements are generally recognized when the related qualified research expenses are incurred. Deferred revenue primarily represents the portion of research or license payments received but not earned.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic 606. The Company’s performance obligations include license rights, development services and services associated with regulatory submission and approval processes. Revenues from research services earned under collaboration agreements are generally recognized as revenue as the related services are provided. Revenues from non-refundable upfront fees are recognized over time either by measuring progress towards satisfaction of the relevant performance obligation, using the input method (i.e. cumulative actual costs incurred relative to total estimated costs) or on a straight-line basis when a performance obligation is expected to be satisfied evenly over a period of time (or when the entity has a stand-ready obligation). Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement, which may include total internal personnel costs and external costs to be incurred as well as, in certain cases, the estimated stand-ready obligation period. Changes in these estimates can have a material effect on revenue recognized. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. The estimated period of performance and project costs, such as personnel and manufacturing cost, are reviewed quarterly and adjusted, as needed, to reflect the Company’s current assumptions regarding the timing of its deliverables.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. Related costs and expenses under these arrangements have historically approximated the revenues recognized.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues from major collaboration agreements and research activity grants as a percentage of total revenues were as follows:</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.425%;"><tr><td style="width:1.0%;"/><td style="width:66.930%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:13.028%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.811%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.031%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Kite Pharma, Inc.</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pfizer</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">N/A </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sanofi</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Receivables from collaborations are typically unsecured and are concentrated in the biopharmaceutical industry. Accordingly, the Company may be exposed to credit risk generally associated with biopharmaceutical companies or specific to its collaboration agreements. To date, the Company has not experienced any losses related to these receivables.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Funds received from third parties under contract or funds received from grant arrangements are generally recorded as revenue if the Company is deemed to be the principal participant in the arrangements because the activities under the contracts or grants are part of the Company’s development programs. Contract funds are not refundable and are recognized when the related qualified research and development costs are incurred and there is reasonable assurance that the funds will be received. Funds received in advance are recorded as deferred revenue.</span></div>
CY2020Q1	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	1500000	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	85749000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	80428000	USD
CY2019Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	80968000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	140418000	USD
CY2020Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1500000	USD
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1500000	USD
CY2019Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	3500000	USD
CY2018Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	3500000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	87249000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	81928000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	84468000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	143918000	USD
CY2020Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Concentrations of Risk</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash, cash equivalents, and marketable securities consist of financial instruments that potentially subject the Company to a concentration of credit risk to the extent of the fair value recorded in the Condensed Consolidated Balance Sheets. The Company invests cash that is not required for immediate operating needs primarily in highly liquid instruments that bear minimal risk. The Company has established guidelines relating to the quality, diversification, and maturities of securities to enable the Company to manage its credit risk. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and investments and issuers of investments to the extent recorded on the Condensed Consolidated Balance Sheets.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Certain materials and key components that the Company utilizes in its operations are obtained through single suppliers. Since the suppliers of key components and materials must be named in an IND application filed with the U.S. Food and Drug Administration for a product, significant delays can occur if the qualification of a new supplier is required. If delivery of material from the Company’s suppliers were interrupted for any reason, the Company may be unable to supply any of its product candidates for clinical trials.</span></div>
CY2020Q1	sgmo	Business Acquisition Number Of Free Shares Outstanding Subject To Purchase BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase	366000	shares
CY2020Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	276794000	USD
CY2020Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	710000	USD
CY2020Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	123000	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	277381000	USD
CY2020Q1	sgmo	Cash Equivalents And Available For Sale Securities Amortized Cost CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost	336403000	USD
CY2020Q1	sgmo	Cash Equivalents And Available For Sale Securities Gross Unrealized Gain Before Tax CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax	710000	USD
CY2020Q1	sgmo	Cash Equivalents And Available For Sale Securities Gross Unrealized Loss Before Tax CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax	123000	USD
CY2020Q1	sgmo	Cash Equivalents And Available For Sale Securities CashEquivalentsAndAvailableForSaleSecurities	336990000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	303546000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	351000	USD
CY2019Q4	sgmo	Cash Equivalents And Available For Sale Securities Gross Unrealized Gain Before Tax CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax	352000	USD
CY2019Q4	sgmo	Cash Equivalents And Available For Sale Securities Gross Unrealized Loss Before Tax CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax	19000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	19000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	303878000	USD
CY2019Q4	sgmo	Cash Equivalents And Available For Sale Securities Amortized Cost CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost	337040000	USD
CY2019Q4	sgmo	Cash Equivalents And Available For Sale Securities CashEquivalentsAndAvailableForSaleSecurities	337373000	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	272381000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	282046000	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	5000000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	21832000	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	277381000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	303878000	USD
CY2019Q1	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	0	USD
CY2020Q1	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	0	USD
CY2019Q4	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0	USD
CY2020Q1	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0	USD
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14849728	shares
CY2019Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11604633	shares
CY2019Q1	sgmo	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress Percentage ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressPercentage	0.38
CY2020Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	2600000	USD
CY2020Q1	us-gaap	Variable Lease Cost VariableLeaseCost	500000	USD
CY2020Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	1600000	USD
CY2020Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y7M6D
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	4298000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	6385000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	6463000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	6551000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	6689000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	26134000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	56520000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	13023000	USD
CY2020Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	43497000	USD
CY2020Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3299000	USD
CY2020Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	40198000	USD
CY2020Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	43497000	USD
CY2020Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.062
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5620000	USD
CY2019Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4523000	USD
CY2019Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	136300000	USD
CY2020Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2019Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2019Q4	us-gaap	Minority Interest MinorityInterest	185000	USD
CY2020Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-61000	USD
CY2020Q1	us-gaap	Minority Interest MinorityInterest	124000	USD

Files In Submission

Name	View Source	Status
0001628280-20-007462-index-headers.html	Edgar Link	pending
0001628280-20-007462-index.html	Edgar Link	pending
0001628280-20-007462.txt	Edgar Link	pending
0001628280-20-007462-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
sgmo-20200331.htm	Edgar Link	pending
sgmo-20200331.xsd	Edgar Link	pending
sgmo-20200331xex102.htm	Edgar Link	pending
sgmo-20200331xex103.htm	Edgar Link	pending
sgmo-20200331xex311.htm	Edgar Link	pending
sgmo-20200331xex312.htm	Edgar Link	pending
sgmo-20200331xex321.htm	Edgar Link	pending
sgmo-20200331xexfe7.htm	Edgar Link	pending
sgmo-20200331xexfe7001.jpg	Edgar Link	pending
sgmo-20200331xexfe7002.jpg	Edgar Link	pending
sgmo-20200331xexfe7003.jpg	Edgar Link	pending
sgmo-20200331xexfe7004.jpg	Edgar Link	pending
sgmo-20200331xexfe7005.jpg	Edgar Link	pending
sgmo-20200331xexfe7006.jpg	Edgar Link	pending
sgmo-20200331xexfe7007.jpg	Edgar Link	pending
sgmo-20200331xexfe7008.jpg	Edgar Link	pending
sgmo-20200331xexfe7009.jpg	Edgar Link	pending
sgmo-20200331xexfe7010.jpg	Edgar Link	pending
sgmo-20200331xexfe7011.jpg	Edgar Link	pending
sgmo-20200331xexfe7012.jpg	Edgar Link	pending
sgmo-20200331xexfe7013.jpg	Edgar Link	pending
sgmo-20200331xexfe7014.jpg	Edgar Link	pending
sgmo-20200331xexfe7015.jpg	Edgar Link	pending
sgmo-20200331xexfe7016.jpg	Edgar Link	pending
sgmo-20200331xexfe7017.jpg	Edgar Link	pending
sgmo-20200331xexfe7018.jpg	Edgar Link	pending
sgmo-20200331xexfe7019.jpg	Edgar Link	pending
sgmo-20200331xexfe7020.jpg	Edgar Link	pending
sgmo-20200331xexfe7021.jpg	Edgar Link	pending
sgmo-20200331xexfe7022.jpg	Edgar Link	pending
sgmo-20200331xexfe7023.jpg	Edgar Link	pending
sgmo-20200331xexfe7024.jpg	Edgar Link	pending
sgmo-20200331xexfe7025.jpg	Edgar Link	pending
sgmo-20200331xexfe7026.jpg	Edgar Link	pending
sgmo-20200331xexfe7027.jpg	Edgar Link	pending
sgmo-20200331xexfe7028.jpg	Edgar Link	pending
sgmo-20200331xexfe7029.jpg	Edgar Link	pending
sgmo-20200331xexfe7030.jpg	Edgar Link	pending
sgmo-20200331xexfe7031.jpg	Edgar Link	pending
sgmo-20200331xexfe7032.jpg	Edgar Link	pending
sgmo-20200331xexfe7033.jpg	Edgar Link	pending
sgmo-20200331xexfe7034.jpg	Edgar Link	pending
sgmo-20200331xexfe7035.jpg	Edgar Link	pending
sgmo-20200331xexfe7036.jpg	Edgar Link	pending
sgmo-20200331xexfe7037.jpg	Edgar Link	pending
sgmo-20200331xexfe7038.jpg	Edgar Link	pending
sgmo-20200331xexfe7039.jpg	Edgar Link	pending
sgmo-20200331xexfe7040.jpg	Edgar Link	pending
sgmo-20200331xexfe7041.jpg	Edgar Link	pending
sgmo-20200331xexfe7042.jpg	Edgar Link	pending
sgmo-20200331xexfe7043.jpg	Edgar Link	pending
sgmo-20200331xexfe7044.jpg	Edgar Link	pending
sgmo-20200331xexfe7045.jpg	Edgar Link	pending
sgmo-20200331xexfe7046.jpg	Edgar Link	pending
sgmo-20200331xexfe7047.jpg	Edgar Link	pending
sgmo-20200331xexfe7048.jpg	Edgar Link	pending
sgmo-20200331xexfe7049.jpg	Edgar Link	pending
sgmo-20200331xexfe7050.jpg	Edgar Link	pending
sgmo-20200331xexfe7051.jpg	Edgar Link	pending
sgmo-20200331xexfe7052.jpg	Edgar Link	pending
sgmo-20200331xexfe7053.jpg	Edgar Link	pending
sgmo-20200331xexfe7054.jpg	Edgar Link	pending
sgmo-20200331xexfe7055.jpg	Edgar Link	pending
sgmo-20200331xexfe7056.jpg	Edgar Link	pending
sgmo-20200331xexfe7057.jpg	Edgar Link	pending
sgmo-20200331xexfe7058.jpg	Edgar Link	pending
sgmo-20200331xexfe7059.jpg	Edgar Link	pending
sgmo-20200331xexfe7060.jpg	Edgar Link	pending
sgmo-20200331xexfe7061.jpg	Edgar Link	pending
sgmo-20200331xexfe7062.jpg	Edgar Link	pending
sgmo-20200331xexfe7063.jpg	Edgar Link	pending
sgmo-20200331xexfe7064.jpg	Edgar Link	pending
sgmo-20200331xexfe7065.jpg	Edgar Link	pending
sgmo-20200331xexfe7066.jpg	Edgar Link	pending
sgmo-20200331xexfe7067.jpg	Edgar Link	pending
sgmo-20200331xexfe7068.jpg	Edgar Link	pending
sgmo-20200331xexfe7069.jpg	Edgar Link	pending
sgmo-20200331xexfe7070.jpg	Edgar Link	pending
sgmo-20200331xexfe7071.jpg	Edgar Link	pending
sgmo-20200331xexfe7072.jpg	Edgar Link	pending
sgmo-20200331xexfe7073.jpg	Edgar Link	pending
sgmo-20200331xexfe7074.jpg	Edgar Link	pending
sgmo-20200331xexfe7075.jpg	Edgar Link	pending
sgmo-20200331xexfe7076.jpg	Edgar Link	pending
sgmo-20200331xexfe7077.jpg	Edgar Link	pending
sgmo-20200331xexfe7078.jpg	Edgar Link	pending
sgmo-20200331xexfe7079.jpg	Edgar Link	pending
sgmo-20200331xexfe7080.jpg	Edgar Link	pending
sgmo-20200331xexfe7081.jpg	Edgar Link	pending
sgmo-20200331xexfe7082.jpg	Edgar Link	pending
sgmo-20200331xexfe7083.jpg	Edgar Link	pending
sgmo-20200331xexfe7084.jpg	Edgar Link	pending
sgmo-20200331xexfe7085.jpg	Edgar Link	pending
sgmo-20200331xexfe7086.jpg	Edgar Link	pending
sgmo-20200331xexfe7087.jpg	Edgar Link	pending
sgmo-20200331xexfe7088.jpg	Edgar Link	pending
sgmo-20200331xexfe7089.jpg	Edgar Link	pending
sgmo-20200331xexfe7090.jpg	Edgar Link	pending
sgmo-20200331xexfe7091.jpg	Edgar Link	pending
sgmo-20200331xexfe7092.jpg	Edgar Link	pending
sgmo-20200331xexfe7093.jpg	Edgar Link	pending
sgmo-20200331xexfe7094.jpg	Edgar Link	pending
sgmo-20200331xexfe7095.jpg	Edgar Link	pending
sgmo-20200331xexfe7096.jpg	Edgar Link	pending
sgmo-20200331xexfe7097.jpg	Edgar Link	pending
sgmo-20200331xexfe7098.jpg	Edgar Link	pending
sgmo-20200331xexfe7099.jpg	Edgar Link	pending
sgmo-20200331xexfe7100.jpg	Edgar Link	pending
sgmo-20200331xexfe7101.jpg	Edgar Link	pending
sgmo-20200331xexfe7102.jpg	Edgar Link	pending
sgmo-20200331xexfe7103.jpg	Edgar Link	pending
sgmo-20200331xexfe7104.jpg	Edgar Link	pending
sgmo-20200331xexfe7105.jpg	Edgar Link	pending
sgmo-20200331xexfe7106.jpg	Edgar Link	pending
sgmo-20200331xexfe7107.jpg	Edgar Link	pending
sgmo-20200331xexfe7108.jpg	Edgar Link	pending
sgmo-20200331xexfe7109.jpg	Edgar Link	pending
sgmo-20200331xexfe7110.jpg	Edgar Link	pending
sgmo-20200331xexfe7111.jpg	Edgar Link	pending
sgmo-20200331xexfe7112.jpg	Edgar Link	pending
sgmo-20200331xexfe7113.jpg	Edgar Link	pending
sgmo-20200331xexfe7114.jpg	Edgar Link	pending
sgmo-20200331xexfe7115.jpg	Edgar Link	pending
sgmo-20200331xexfe7116.jpg	Edgar Link	pending
sgmo-20200331xexfe7117.jpg	Edgar Link	pending
sgmo-20200331xexfe7118.jpg	Edgar Link	pending
sgmo-20200331xexfe7119.jpg	Edgar Link	pending
sgmo-20200331xexfe7120.jpg	Edgar Link	pending
sgmo-20200331xexfe7121.jpg	Edgar Link	pending
sgmo-20200331xexfe7122.jpg	Edgar Link	pending
sgmo-20200331xexfe7123.jpg	Edgar Link	pending
sgmo-20200331xexfe7124.jpg	Edgar Link	pending
sgmo-20200331_cal.xml	Edgar Link	unprocessable
sgmo-20200331_def.xml	Edgar Link	unprocessable
sgmo-20200331_htm.xml	Edgar Link	completed
sgmo-20200331_lab.xml	Edgar Link	unprocessable
sgmo-20200331_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SGMO
Sangamo Therapeutics Inc Stock $sgmo

2020 Q1 Form 10-Q Financial Statement

#000162828020007462 Filed on May 11, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SGMO Sangamo Therapeutics Inc Stock $sgmo

2020 Q1 Form 10-Q Financial Statement

#000162828020007462 Filed on May 11, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SGMO
Sangamo Therapeutics Inc Stock $sgmo